Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol

• Κύριοι συγγραφείς: Chu-Hsun Lu (Συγγραφέας), Yu-Feng Huang (Συγγραφέας), I-Ming Chu (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: MDPI AG, 2022-01-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Sobrerol, an oral mucolytic agent, in a recent study showed promise for treating multiple sclerosis. A human equivalent dose of 486 mg of sobrerol administered thrice daily (i.e., 1459 mg of daily dose) demonstrated the highest therapeutic efficacy for repurposing use, which also points out the poor...